Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.44 |
| ▸ | JAK2 | O60674 | 9/20 | 0.44 |
| ▸ | JAK1 | P23458 | 9/20 | 0.44 |
| ▸ | TYK2 | P29597 | 8/20 | 0.44 |
| ▸ | JAK3 | P52333 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27028607 | 1.00 | IRAK4 (0.44) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27028634 | 0.92 | IRAK4 (0.45) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29958733 | 0.92 | IRAK4 (0.45) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27028684 | 0.91 | IRAK4 (0.42) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29958876 | 0.90 | IRAK4 (0.44) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27028600 | 0.90 | IRAK4 (0.44) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29958828 | 0.90 | IRAK4 (0.46) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27028659 | 0.90 | IRAK4 (0.46) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29958673 | 0.90 | IRAK4 (0.43) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29958986 | 0.89 | PLK1 (0.41) | IRAK4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279240-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-08-22 | — | — | US | claimed |
| EP-4308122-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-01-24 | — | — | EP | claimed |
| CN-116981459-A | Heterocyclic derivatives as janus kinase inhibitors | 奇斯药制品公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2022194779-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279240-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | IRAK4 9/4885JAK2 4/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.